Axel Merseburger, Enrique Grande and María-José Juan-Fita are faced with a challenge to find the best treatment approach for different metastatic urothelial carcinoma (mUC) case studies. They might not agree, but each one will have an opportunity to challenge the other’s viewpoint to create a lively debate.
Watch these two video discussions to expand your knowledge of first- and subsequent-line immunotherapy treatment options and see how the experts work together to find possible solutions.
After studying the content, participants will be able to:
This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany
All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.